... Castilla-Llorente; Nathalie Contentin; Anne Huynh; Ibrahim Yakoub-Agha; Claude-Eric Bulabois; Marie-Thérèse Rubio; Maud D’Aveni Introduction: Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) remains the best curative option for high-risk myelodysplastic syndrome (MDS) and acute myeloid...

...Cecily Allen; Samir Gautam; Wei Cheng; Alexander B. Pine; Nikolai A. Podoltsev; Amer M Zeidan; Alfred I Lee; Rory M. Shallis Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) often receive antibacterial prophylaxis. Antibacterial agents can cause elevations...

... with hypomethylating agents (HMAs). Methods: We performed next-generation sequencing on bone marrow aspiration samples of 59 patients diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome with excess blasts-2, or chronic myelomonocytic leukemia and treated with decitabine or azacitidine as a frontline...

...) and myelodysplastic syndrome (MDS) but with significant non-relapse mortality (NRM) and relapse. We compared the combination of anti-thymocyte globulin (ATG; 4.5 mg/kg) and post-transplant cyclophosphamide (PTCy; 50 mg/kg on day +3 and +4) with other graft-versus-host disease (GvHD) prophylaxis regimens used...

...Federica Pilo; Giovanni Caocci; Giannalisa Mele; Giorgio La Nasa Low-risk patients with myelodysplastic syndromes (MDS) are inclined to long-term accumulation of iron in the organs due mostly to red blood cell transfusion and ineffective erythropoiesis. The effect of free toxic iron species...

... leukemia Chronic leukemia Myelodysplastic syndrome COVID-19 The novel betacoronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was initially described in Wuhan, China, in December 2019. Since then, more than 2.5 million people worldwide have been infected with coronavirus...

...Giulio Giordano; Marco Alfio Cutuli; Alessandro Lucchesi; Irene Magnifico; Noemi Venditti; Franca Vergalito; Maurizio Gasperi; Roberto Di Marco Refractory anaemia (RA) among myelodysplastic syndrome (MDS) is associated with a partial functional iron deficit and may require transfusions. In low-risk...

...Akihiro Takeuchi; Osamu Imataki; Hiroyuki Kubo; Akihiro Kondo; Kayoko Seo; Makiko Uemura; Genji Yamaoka; Koji Murao; Akihiro Takeuchi Background: Myelodysplastic syndromes (MDS) and idiopathic cytopenia of undetermined significance (ICUS) are heterogeneous hematological disorders characterized...

... for the treatment of myelodysplastic syndrome (MDS) is 20 mg/m 2 /day for 5 consecutive days with a relatively high incidence of treatment-related morbidities and costs. In this study, a retrospective and multicenter analysis was performed to explore the very-low-dose decitabine schedule for the treatment...

...Yali Du; Zhangbiao Long; Miao Chen; Bing Han; Bo Hou; Feng Feng Background: This study focuses on the iron overload (IOL) of patients with transfused aplastic anemia (AA) or a low/intermediate-1 risk of myelodysplastic syndrome (MDS). Methods: Ninety-two AA or MDS patients with IOL were...

... chemotherapy and their relationship with markers of immunoparalysis in leukemia patients. In 6 patients with acute myeloid leukemia or myelodysplastic syndrome and 12 healthy subjects, DAMPs, cytokines, and markers of immunoparalysis were determined before and during the first week after chemotherapy...

...Joji Nagasaki; Yasutaka Aoyama; Masayuki Hino; Kentaro Ido; Hiroyoshi Ichihara; Masahiro Manabe; Tadanobu Ohta; Atsuko Mugitani Background/Aims: A high expression of Wilms tumor 1 ( WT1 ) mRNA occurs in most cases of acute leukemia and myelodysplastic syndrome (MDS). Although there are many reports...

... for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2010;45:872-876. 11. Bolanos-Meade J, Smith BD, Gore SD, McDevitt MA, Luznik L, Fuchs EJ, Jones RJ: 5-Azacytidine as salvage treatment in relapsed...

...Ofir Wolach; Richard Stone Autoimmune and inflammatory conditions (AICs) are encountered in up to 25% of patients with myelodysplastic syndromes (MDS). A wide range of AICs have been reported in association with MDS and can range from limited clinical manifestations to systemic diseases affecting...

...Sue Harnan; Shiji Ren; Tim Gomersall; Emma S. Everson-Hock; Anthea Sutton; Sujith Dhanasiri; Austin Kulasekararaj Introduction: Multiple studies show that transfusion independence (TI) in myelodysplastic syndrome (MDS) has a positive impact on overall survival (OS). To assess this, a systematic...

...Dolors Costa; Concha Muñoz; Ana Carrió; Amparo Arias; Cándida Gómez; Francesc Solé; Blanca Espinet; Gemma Azaceta; María J. Calasanz; Meritxell Nomdedeu; Xavier Calvo; Elias Campo; Benet Nomdedeu Recurrent translocations are uncommon in myelodysplastic syndromes (MDS). Three new recurrent...

.../MDS Working Party Azacitidine (AZA) is commonly used in patients with myelodysplastic syndrome (MDS). To determine the role of AZA before allogeneic stem cell transplantation (allo-SCT), we conducted a prospective study of AZA pre-treatment followed by allo-SCT in patients with higher-risk MDS. Twenty...

...Yunsuk Choi; Sung-Doo Kim; Young-Hoon Park; Jae Seok Lee; Dae-Young Kim; Jung-Hee Lee; Kyoo-Hyung Lee; Miee Seol; Young-Shin Lee; Young-Ah Kang; Mijin Jeon; Ah Rang Jung; Je-Hwan Lee In patients with secondary acute myeloid leukemia (s-AML) arising from the myelodysplastic syndrome (MDS), treatment...

...-induced or malignancy-associated entity. SS is also seen in patients with myelodysplastic syndrome (MDS) where it may present atypically, both clinically and histologically. In a few rare cases of MDS, lymphocytic infiltrates are the presenting feature of SS. Methods: MEDLINE and Scopus were the data...

...Aleksandar Savic; Dragomir Marisavljevic; Vanja Kvrgic; Natasa Stanisavljevic The objective of this study is to externally validate the recently published Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome (MDS) and compare it with the International Prognostic...